• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study shows no benefit for Exogen bone stim from Bioventus

Study shows no benefit for Exogen bone stim from Bioventus

October 26, 2016 By Fink Densford

BioventusA new study, published yesterday in the BMJ, is casting doubts on the healing benefit of Bioventus‘s Exogen ultrasound bone stimulator.

The Durham, N.C.-based company’s Exogen is designed to use low-intensity pulsed ultrasound to “help stimulate the body’s natural healing process.” Bioventus touts an 86% healing rate for fractures not healing on their own and 38% faster healing of fresh fractures with use of the device.

Results from the trial indicated no benefit from the use of the device, with no difference in time to radiographic healing between the cohorts, no differences to safety outcomes or in any other functional treatments.

Data from the trial also indicated no SF-36 PCS score difference between the LIPUS and the sham cohort.

“Among patients undergoing intramedullary nailing for a tibial shaft fracture the addition of low intensity pulsed ultrasound does not improve functional recovery or accelerate radiographic healing,” study authors wrote.

The trial had sites in the U.S. and Canada and enrolled 501 patients who required surgical repair of tibia fractures to test the effectiveness of low intensity pulsed ultrasound treatments.

Patients were split between either self administered daily LIPUS use, or the use of a sham device until the tibial fracture showed radiographic healing, or 1 year after intramedullary fixation.

Primary outcomes were specified as time to radiographic healing within 1 year of fixation, with a secondary outcome set as the rate of non-union. Additional outcomes included a short form-36 physical component summary scores, time to return to work, return to household activities, return to leisure activities, full weight bearing and return to greater than or equal to 80% of function before injury.

“The FDA approved LIPUS for fracture healing in 1994 on the basis of small trials at high risk of bias that showed that LIPUS accelerated radiographic healing. Many medical devices, however, are approved for sale without randomized trial evidence of important benefit to patients,” study authors wrote. “A study published in 2016 found that of 99 medical devices recently approved by the FDA, 43 were cleared or approved before a clinical study was published. Further, as is the case with LIPUS, device inventors or industry employees are often investigators on clinical trials that are used to gain regulatory approval. Our experience suggests the high desirability of demanding evidence from randomized trials conducted by investigators other than those who will gain financially from clinical use of the device before approval by regulatory agencies.”

In September, Bioventus said it launched the Exogen ultrasound bone healing system in Saudi Arabia.

In July, Bioventus postponed an initial public offering which was slated to raise up to $150 million. The company had planned to float 8.8 million shares at a price range of between $16 and $18, and would have listed on the NASDAQ exchange under the “BIOV” ticker. The proceeds were earmarked for paying down debt.

Filed Under: Clinical Trials, Orthopedics Tagged With: Bioventus LLC

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy